Q2-osavuosiraportti
Vain PDF
63 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
5 000
Myynti
Määrä
15 678
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,31VWAP
Alin
2,12VaihtoMäärä
0,3 141 951
VWAP
Ylin
2,31Alin
2,12VaihtoMäärä
0,3 141 951
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
17.10.·Why is it constantly going down? Anyone knowledgeable know?
20 t sitten·One could be that someone has intended to buy the company and therefore drive down the price and buy the company cheaply.
7.10.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company will participate in Redeye Neurology Day on October 15 at 11:40 AM where CEO Martin Jönsson and CSO Johan Sandin will give a company presentation and answer questions about the latest developments and AlzeCure's plans going forward.
8.10.·Stop making noise on this channel - there is absolutely no value in your posts, so stop it now!
11.9.·Why this big drop?11.9.·Maybe some have sold large items but this stock will hold out.- 8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
63 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 17.10.·Why is it constantly going down? Anyone knowledgeable know?20 t sitten·One could be that someone has intended to buy the company and therefore drive down the price and buy the company cheaply.
- 7.10.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company will participate in Redeye Neurology Day on October 15 at 11:40 AM where CEO Martin Jönsson and CSO Johan Sandin will give a company presentation and answer questions about the latest developments and AlzeCure's plans going forward.8.10.·Stop making noise on this channel - there is absolutely no value in your posts, so stop it now!
- 11.9.·Why this big drop?11.9.·Maybe some have sold large items but this stock will hold out.
- 8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
5 000
Myynti
Määrä
15 678
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,31VWAP
Alin
2,12VaihtoMäärä
0,3 141 951
VWAP
Ylin
2,31Alin
2,12VaihtoMäärä
0,3 141 951
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
63 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 17.10.·Why is it constantly going down? Anyone knowledgeable know?20 t sitten·One could be that someone has intended to buy the company and therefore drive down the price and buy the company cheaply.
- 7.10.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company will participate in Redeye Neurology Day on October 15 at 11:40 AM where CEO Martin Jönsson and CSO Johan Sandin will give a company presentation and answer questions about the latest developments and AlzeCure's plans going forward.8.10.·Stop making noise on this channel - there is absolutely no value in your posts, so stop it now!
- 11.9.·Why this big drop?11.9.·Maybe some have sold large items but this stock will hold out.
- 8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
5 000
Myynti
Määrä
15 678
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,31VWAP
Alin
2,12VaihtoMäärä
0,3 141 951
VWAP
Ylin
2,31Alin
2,12VaihtoMäärä
0,3 141 951
Välittäjätilasto
Dataa ei löytynyt